Oslo, Norway, 8 May 2024 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The Company has received approval to start its first APC148 phase 1 clinical trial by the Swedish medical products agency.
Adjutec submitted, earlier this year, an application to the Swedish authority for starting a single-dose-ascending study of APC148 in healthy volunteers. The study will give Adjutec valuable human pharmacokinetic and safety data of our lead compound. An approval was anticipated before summer, but the process with the Swedish authority was constructive and smooth, which accelerated the approval.
The manufacturing of APC148 drug product is on-going and the study will commence shortly after the summer at the facilities of Clinical Trials Consultants AB (CTC) in Uppsala, Sweden.
“This is excellent news, reaching an important milestone in the short history of Adjutec. With limited resources, we have been able to reach the clinical phase of APC148 development. It has been a fabulous effort from our team and our collaborators. The approval is a great motivation to continue preparations for the upcoming clinical studies in 2025”, comments Bjørg Bolstad, CCRO (Clinical & Regulatory) of AdjuTec Pharma.
Full PR available here